Brent Ogilvie has extensive life science commercialisation experience, specifically in venture development and investment, including the early funding formation of New Zealand diabetes (ASX:LCT), multiple sclerosis (ASX:IIL) and cystic fibrosis (Breathe Easy Limited) drug development companies.
Dr. Pablo German
Director & Chief Technical Officer
Pablo German, Founding Director, has experience in the study of molecular targets through his doctoral studies. His experience includes being Research Manager at Comvita, the world’s largest producer of Manuka honey. Pablo has held a number of leadership roles and has been the recipient of several scholarships and awards.
Brett Oliver has more than ten years of experience in commercialisation and innovation activities. His past roles included technology auditor and advisor at KPMG, commercialisation manager at NZ’s largest research organisation, and innovation manager at NZ national health innovation initiative. Brett is also experienced in composite materials engineering, venture capital due-diligence, commercial and property finance.
Joseph Lupi has extensive experience in the commercial sector. A continuous recipient of the Gold award, he has impacted the New Zealand and international markets in a substantial manner. Joseph has supported his community and charities throughout his career with involvement in multiple cancer research facilities and other community projects.
Kieran Jina has experience in providing operational support to early stage ventures through his roles as Operations Manager for Engender Technologies and Orbis Diagnostics,and Senior Associate at life sciences investment firm Pacific Channel. He holds degrees in Master of Science (Hons) in Biomedical Science and Master of Bioscience Enterprise (Hons) from the University of Auckland. Kieran was previously the Market Analyst at Aroa Biosurgery.
Dr. John Arabshahi
Drug Design & Development
John Arabshahi has experience in the development and design of drugs using In silico screening methods. His doctoral studies focused on the use of natural products for virtual screening and drug development. His experience includes developing lead compounds in a variety of targets, docking studies, peptide docking and homology modelling.